ClinicalTrials.gg
CompletedNCT05292495Updated May 22, 2026

A Trial of HR17031 Injection With Renal Insufficiency

A Phase 1 interventional study of HR17031 injection in Improved Glycemic Control in Patients With Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
58th of 81
24 · median 80
Started
2022
with 3 others
Phase 1
48 of 81
4 open now
Registered
40th of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 58th largest by enrollment, is one of 4 that started in 2022, is one of 48 in phase 1, and was the 40th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild, moderate and severe renal insufficiency and end-stage renal disease and subjects with normal renal function.

03

Conditions studied

  • Improved Glycemic Control in Patients With Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Renal impairment subjects Inclusion Criteria:

  1. Signed the before the test, and fully understood the test content, process and possible adverse reactions; And able to complete the research according to the requirements of the test protocol.
  2. Age 18-70 (including threshold), male and female.
  3. (BMI): 18\~30 kg/m2 (including critical value).
  4. (CLcr, calculated by the Cockcroft-Gault formula) must meet the following criteria: Subjects with mild renal insufficiency: 60-89 mL/min (including cutoffs); Subjects with moderate renal impairment: 30-59 mL/min (including cutoffs); Subjects with severe renal impairment: 15-29 mL/min (including cutoffs); Subjects with end-stage renal insufficiency: \<15 mL/min.
  5. The renal function status is stable, and the CLcr results of the two tests before administration (the two tests need to be separated by at least 3 days, but within 14 days) should be within ±25%. If the second result is not within ±25%, a third test can be performed (at least 3 days from the second test, but within 14 days). The third test result needs to be within ±25% of the second test result. Calculation formula: (third result - second result)/second result. The test results within 24 hours before administration will be used for the final trial grouping and subsequent PK analysis.
  6. Females of childbearing age must take reliable measures and be willing to use appropriate methods of contraception during the trial and within 10 weeks after the last administration of the test drug; male subjects are willing to have no reproductive plans during the trial and within 10 weeks after the last administration of the test drug and Voluntary use of effective contraception, or surgical sterilization.
  7. For patients with other underlying diseases requiring drug treatment, the dose needs to be kept stable during this study.

B. Healthy subjects Inclusion Criteria:

  1. Signed the informed consent before the test, and fully understood the test content, process and possible adverse reactions; And able to complete the research according to the requirements of the test protocol.
  2. Able to complete the research in accordance with the requirements of the experimental protocol.
  3. Age 18-70 (including threshold), male and female.
  4. Body mass index (BMI): 18\~30 kg/m2 (including critical value).
  5. Creatinine clearance rate (CLcr, calculated by Cockcroft-Gault formula) ≥ 90mL/min.
  6. The renal function status is stable, and the CLcr results of the two tests before administration (the two tests need to be separated by at least 3 days, but within 14 days) should be within ±25%. Calculation formula: (second result - first result)/first result. The test results within 24 hours before administration will be used for the final trial grouping and subsequent PK analysis.
  7. Females of childbearing age must take reliable contraceptive measures and be willing to use appropriate methods of contraception during the trial and within 10 weeks after the last administration of the test drug; male subjects are willing to have no reproductive plans during the trial and within 10 weeks after the last administration of the test drug and Voluntary use of effective contraception, or surgical sterilization.

Exclusion criteria

Exclusion Criteria:

A. Exclusion Criteria for subjects with mild, moderate and severe renal impairment:

  1. Have done kidney transplantation.
  2. Renal dialysis is required during the study.
  3. Those with allergic constitution, including those with a history of severe drug allergy or drug allergy, or known or suspected to be allergic to any component in the study drug.
  4. Urinary incontinence or anuria (eg \<100ml/d).
  5. Those who have a history of drug and/or alcohol abuse, who are positive for alcohol and drug screening, or who have a history of drug abuse in the past five years or who have used drugs in the 3 months before the test; and who cannot smoke or abstain from alcohol during the test.
  6. Pregnant or lactating women, or those with a positive blood pregnancy result.
  7. Those who donated blood or participated in any clinical trial drugs within 3 months before screening.
  8. Those who have taken other prescription drugs, over-the-counter drugs, Chinese herbal medicines or food supplements other than those used to treat renal insufficiency and other concomitant diseases within 14 days before administration.
  9. Combined with other viral infections (anti-, anti- positive, positive or combined with positive syphilis serology).
  10. Major surgery or surgical incision was not fully healed within 6 months before screening.
  11. History or clinical symptoms of deep vein thrombosis or other thromboembolic events suggest thrombophilia.
  12. Active heart disease within 6 months before the first administration of the study drug, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure and ventricular arrhythmia requiring drug treatment.
  13. Have a history of epilepsy, or a disease that can induce epileptic seizures within 12 months before the first administration of the study drug (including a history of , cerebral apoplexy (except for cerebral ischemic lesions found by simple imaging examination), Brain trauma with disturbance of consciousness requires hospitalization).
  14. Malignant tumors, or a history of malignant tumors within 5 years before screening (except for skin non-melanoma that has been treated and has no signs of recurrence, and excised cervical intraepithelial neoplasia).
  15. In addition to renal insufficiency and other concomitant diseases, the researcher makes judgments based on medical history inquiry, comprehensive physical examination, routine laboratory tests (blood routine, blood biochemistry, urine routine, etc.), X-chest X-ray, abdominal B-ultrasound, etc. Abnormal clinical significance.
  16. 12- abnormality with clinical significance and uncontrollable by drugs (if uncontrolled tachycardia/bradycardia, II-III degree atrioventricular block or prolongation of interval (male ≥ 470 ms, female ≥ 470 ms) 480 ms) (corrected by Fridericia's formula) or other abnormalities judged by the clinician).
  17. 48 hours before taking the study drug until the end of the study, the subject refuses to stop any beverages containing methylxanthine, such as caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any fruit juice.
  18. Vigorous exercise within 48 hours before administration, or other factors affecting drug distribution, metabolism, excretion, etc..
  19. Those with a history of fainting, fainting of blood, difficult to collect blood or unable to tolerate venipuncture for blood collection.
  20. Those who have used insulin or glucagon-like polypeptide-1 receptor agonist (GLP-1) hypoglycemic drugs within 3 months before screening.
  21. Those who have been vaccinated or exposed to other or live attenuated vaccines within 3 months before screening; or those who plan to receive live vaccines or live attenuated vaccines during the study period.
  22. According to the judgment of the researcher, there are concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease and mental illness, etc.) or any other conditions that seriously endanger the safety of patients, or affect the completion of the study.

B. Exclusion Criteria for ESRD:

  1. Have done kidney transplantation.
  2. Those with allergic constitution, including those with a history of severe drug allergy or drug allergy, or known or suspected to be allergic to any component of the study drug.
  3. Urinary incontinence or anuria (eg \<100ml/d).
  4. Those who have a history of drug and/or alcohol abuse, who are positive for alcohol and drug screening, or who have a history of drug abuse in the past five years or who have used drugs in the 3 months before the test; and who cannot smoke and abstain during the test.
  5. Pregnant or lactating women, or those with a positive blood pregnancy result.
  6. Those who donated blood or participated in any clinical trial drug within 3 months before screening.
  7. Those who have taken other prescription drugs, over-the-counter drugs, Chinese herbal medicines or food supplements other than those used to treat renal insufficiency and other concomitant diseases within 14 days before administration.
  8. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive or combined with positive syphilis serology).
  9. Received major surgery within 6 months before screening or the surgical incision was not completely healed.
  10. History or clinical symptoms of deep vein thrombosis or other thromboembolic events suggest thrombophilia.
  11. Active heart disease within 6 months before the first administration of the study drug, including: severe/unstable angina, myocardial infarction, symptomatic congestive heart failure and ventricular arrhythmia requiring drug treatment.
  12. Have a history of epilepsy, or a disease that can induce epileptic seizures within 12 months before the first administration of the study drug (including a history of transient ischemic attack, cerebral apoplexy (except for cerebral ischemic lesions found by simple imaging examination), Brain trauma with disturbance of consciousness requires hospitalization).
  13. Suffering from malignant tumor, or a history of malignant tumor within 5 years before screening (except for skin non-melanoma that has been treated and has no signs of recurrence, and excised cervical intraepithelial neoplasia).
  14. In addition to renal insufficiency and other concomitant diseases, the researcher makes judgments based on medical history inquiry, comprehensive physical examination, routine laboratory tests (blood routine, blood biochemistry, urine routine, etc.), X-chest X-ray, abdominal B-ultrasound, etc. Abnormal clinical significance.
  15. 12-ECG abnormality is clinically significant and uncontrollable by drugs (if uncontrolled tachycardia/bradycardia, II-III degree atrioventricular block or prolongation of QTcF interval (men ≥ 470 ms, women ≥ 470 ms) 480 ms) (corrected by Fridericia's formula) or other clinically significant abnormalities judged by the clinician).
  16. 48 hours before taking the study drug until the end of the study, the subject refuses to stop any beverages containing methylxanthine, such as caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any fruit juice.
  17. Vigorous exercise within 48 hours before administration, or other factors affecting drug distribution, metabolism, excretion, etc..
  18. Those with a history of fainting of needles, fainting of blood, difficulty in blood collection or intolerance of venipuncture for blood collection.
  19. Those who have used insulin or glucagon-like polypeptide-1 receptor agonist (GLP-1) hypoglycemic drugs within 3 months before screening.
  20. Those who have been vaccinated or exposed to other live vaccines or live attenuated vaccines within 3 months before screening; or those who plan to receive live vaccines or live attenuated vaccines during the study period.
  21. According to the judgment of the researcher, there are concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease and mental illness, etc.) or any other conditions that seriously endanger the safety of patients, or affect the completion of the study.

C. Exclusion Criteria for Healthy subject:

  1. Chronic kidney disease damage and kidney transplantation.
  2. Those with allergic constitution, including those with a history of severe drug allergy or drug allergy, or known or suspected to be allergic to any component of the study drug.
  3. Those who have a history of drug and/or alcohol abuse, who are positive for alcohol and drug screening, or who have a history of drug abuse in the past five years or who have used drugs in the 3 months before the test; and who cannot smoke or abstain from alcohol during the test.
  4. Pregnant or breastfeeding women, or those with a positive blood pregnancy result.
  5. Those who donated blood or took any clinical trial drugs within 3 months before screening.
  6. Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or food supplements within 14 days before administration.
  7. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive or combined with positive syphilis serology).
  8. Those who have undergone any surgery within 6 months before screening.
  9. History or clinical symptoms of deep vein thrombosis or other thromboembolic events suggest thrombophilia.
  10. Active heart disease within 6 months before the first administration of the study drug, including: severe/unstable angina, myocardial infarction, symptomatic congestive heart failure and ventricular arrhythmia requiring drug treatment.
  11. Have a history of epilepsy, or a disease that can induce epileptic seizures within 12 months before the first administration of the study drug (including history of transient ischemic attack, cerebral apoplexy (except for cerebral ischemic foci found by simple imaging examination), Brain trauma with disturbance of consciousness requires hospitalization).
  12. Suffering from malignant tumor, or a history of malignant tumor within 5 years before screening (except for skin non-melanoma that has been treated and has no signs of recurrence, and excised cervical intraepithelial neoplasia).
  13. Comprehensive physical examination (vital signs, physical examination), routine laboratory examinations (blood routine, blood biochemistry, urine routine, thrombin function, etc.), X-chest X-ray, abdominal B-ultrasound and other abnormal examinations with clinical significance.
  14. 12-ECG abnormalities with clinical significance and uncontrollable by drugs (if uncontrolled tachycardia/bradycardia, II-III degree atrioventricular block or prolongation of QTcF interval (≥470 ms in males, ≥470 ms in females) 480 ms) (corrected by Fridericia's formula) or other clinically significant abnormalities judged by the clinician).
  15. 48 hours before taking the study drug until the end of the study, the subject refuses to stop any beverages containing methylxanthine, such as caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any fruit juice.
  16. Vigorous exercise within 48 hours before administration, or other factors affecting drug distribution, metabolism, excretion, etc..
  17. Those with a history of needle fainting, haemorrhage, difficulty in blood collection or intolerance of venipuncture for blood collection.
  18. Those who have used insulin or glucagon-like polypeptide-1 receptor agonist (GLP-1) hypoglycemic drugs within 3 months before screening.
  19. Those who have been vaccinated or exposed to other live vaccines or live attenuated vaccines within 3 months before screening; or those who plan to receive live vaccines or live attenuated vaccines during the study period.
  20. According to the judgment of the investigator, there are concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease and mental illness, etc.) or any other conditions that seriously endanger the safety of patients, or affect the completion of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort one: mild renal insufficiency

    Drug: HR17031 injection

  • Experimental
    Cohort two: moderate renal insufficiency

    Drug: HR17031 injection

  • Experimental
    Cohort three: severe renal insufficiency

    Drug: HR17031 injection

  • Experimental
    Cohort four: end-stage renal disease

    Drug: HR17031 injection

  • Experimental
    Cohort five: normal renal function

    Drug: HR17031 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameters of INS068 and SHR20004: Cmax

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  2. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  3. Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

Secondary outcomes

  1. Pharmacokinetics parameters of INS068 and SHR20004: Tmax

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  2. Pharmacokinetics parameters of INS068 and SHR20004: T1/2

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  3. Pharmacokinetics parameters of INS068 and SHR20004: CL/F

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  4. Pharmacokinetics parameters of INS068 and SHR20004: Vz/F

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  5. Pharmacokinetics parameters of INS068 and SHR20004: Ae

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  6. Pharmacokinetics parameters of INS068 and SHR20004: fe

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  7. Pharmacokinetics parameters of INS068 and SHR20004: CLr

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  8. Average concentrations of INS068 and SHR20004 in dialysate of ESRD

    Time frame: 0- 4 hours post-dose sampling times

  9. Cumulative collection amount of INS068 and SHR20004 in dialysate of ESRD

    Time frame: 0- 4 hours post-dose sampling times

  10. Dialysis clearance of INS068 and SHR20004 in dialysate of ESRD

    Time frame: 0- 4 hours post-dose sampling times

  11. Binding rate of plasma protein of INS068 in serum and SHR20004 in plasma(fu)

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  12. The incidence and severity of adverse events/serious adverse events

    Time frame: Based on pre-dose, 2-96 hours post-dose sampling times

  13. ADA:anti-drug antibody

    Time frame: Based on pre-dose、Day 5、Day14、Day 24 or early termination

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality 100009, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2024, 17 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 17 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Mar 23, 2022
StartActual
Oct 12, 2022
Primary completionActual
Apr 10, 2024
CompletionActual
Apr 10, 2024
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05292495
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Oct 12, 2022
Primary completion
Apr 10, 2024
Completion
Apr 10, 2024
Last update
May 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR17031

Start the discussion